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Puberty is a crucial time for bone development with a doubling
of skeletal mass and at least 90% of bone mineral deposition
accrued by the end of adolescence [1]. Following puberty, bone
mineral deposition continues with peak bone mass typically
obtained around the age of 25 years [2]. The accrual of bone mass
during adolescence is a major determinant of peak bone mass [1]
and low peak bone mass is associated with osteoporosis later in
life [3].
Low bone mineral density (BMD) has been reported in children
living with perinatally acquired HIV infection (PaHIV) [4]. However,
adults with PaHIV are a unique group in whom the effects of
lifelong HIV infection and antiretroviral therapy (ART) on BMD
remains unknown.
We report on BMD and factors associated with reductions in BMD
for all PaHIV-positive adults who attended a London clinic between
May 2014 and October 2016.
The number of PaHIV-positive young adults included was 158.
Median age was 22 (IQR, 19–25) years. Ninety-one (57.6%) were
female and 149 (94.3%) were of non-white (black, mixed-race,
Asian or other) ethnicity. Latest median CD4 count was 591
cells/mm3 (IQR, 425–768). One hundred and fifty (94.9%) patients
were on ART of whom 121 (80.7%) had a plasma HIV viral load
<50 copies/mL at their last visit. Thirty (19.0%) patients were
current or ex-smokers; either cigarettes and/or cannabis. Four out
of 91 (4.4%) patients were underweight (BMI <18.5). At least
94 (59.5%) patients had been exposed to tenofovir disoproxil
fumarate (TDF) in their lifetime. Three (3.3%) female patients
reported Depo-Provera use. Median 25-hdroxyvitamin D (25-OHD)
was 12.8 ng/ml (IQR, 9.6–20.4). Out of 107 patients, 77 (74.8%)
were currently deficient in 25-OHD (<20 ng/ml).
Sixteen patients received dual energy x-ray absorptiometry scans
assessing lumbar spine and femoral neck BMD. Fifteen (94%)
patients were scanned for clinical indicators; one (6%) during a
clinical trial. Two (12.5%) patients had lumbar spine or femoral
Z-scores <−2.5. Six (37.5%) patients had lumbar spine or femoral
Z-scores between -1 and -2.
Sudjaritruk et al. recently reported low BMD in a Thai and
Indonesian cohort of PaHIV-positive adolescents aged 10–18 years
[4]. In agreement with Sudjaritruk et al. we observed a high
prevalence of reductions in BMD. We observed a higher than
expected prevalence of factors associated with adverse bone
health, namely vitamin D deficiency; a key difference being that
the majority of our cohort were individuals of African or mixed-race
origin living in the UK, with significantly less exposure to sunlight.
Long-term outcomes with regard to osteoporosis and risk of
fracture in adults with PaHIV remain unknown. However, higher
than expected prevalence of reductions in BMD suggest that
optimisation of bone health should be made a priority in this group.
Tenofovir alafenamide (TAF) is now a recommended alternative
to TDF and early data suggest more favourable bone outcomes
[5]. The revised NHS England clinical commissioning policy for
the use of TAF highlights groups that are most at risk of bone
disease, including adolescents and young adults under 25 years
of age [2]. There is an increasing body of evidence supporting
switching from TDF to TAF to maximise peak bone mass for this
age group.
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